Skip to main content

Advertisement

SpringerLink
Log in

The Use of Oxytocin for the Treatment of Opioid Use Disorder

  • Acute Pain Medicine (R Urman, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Nearly 27 million people have an opioid use disorder (OUD) according to the 2016 Global Burden of Disease study, most of which occur in the US where opioids are a common class of medication used to treat acute and chronic pain. In 2016 alone, more than 60 million patients had at least one prescription for opioids filled or refilled. Over the past decade, prescription rates have risen astronomically and have created an epidemic in the US dubbed the “opioid crisis.” In this regard, there has been an increase in overdoses and OUD diagnoses. Several studies have found dysregulation of balance between several neurotransmitters involved in the neural circuitry that subserves several behavioral domains, such as reward recognition, motivation, learning, and memory, affect, stress, and executive function, that contribute to the manifestation of craving. On the horizon is a new treatment approach consisting of the neuropeptide oxytocin, which may be involved in the overlapping mechanisms of stable attachment formation and coping with stress. Through this mechanism, it can shift processing from novelty and reward-seeking to an appreciation of familiarity and thus reduce stress and increase resilience in the face of addiction. It has been hypothesized that there is a connection between the glutaminergic and oxytocinergic systems, making oxytocin a possible therapeutic agent in reducing drug-induced actions seen in OUD patients. This manuscript will review the potential and feasible use of oxytocin in treating OUD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hagemeier NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care. 2018;24(10 Suppl):S200–6.

    PubMed  Google Scholar 

  2. Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The opioid crisis: a comprehensive overview. Curr Pain Headache Rep. 2018;22(3):16. https://doi.org/10.1007/s11916-018-0670-z.

    Article  PubMed  Google Scholar 

  3. Taylor JL, Samet JH. Opioid use disorder. Ann Intern Med. 2022;175(1):ITC1–16. https://doi.org/10.7326/AITC202201180.

    Article  PubMed  Google Scholar 

  4. Strang J, et al. Opioid use disorder. Nat Rev Dis Primer. 2020;6(1):3. https://doi.org/10.1038/s41572-019-0137-5.

    Article  Google Scholar 

  5. Edinoff AN, et al. Alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: a narrative review of clinical evidence. Neurol Int. 2022;14(2):423–36. https://doi.org/10.3390/neurolint14020035.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Edinoff AN, et al. Naltrexone implant for opioid use disorder. Neurol Int. 2021;14(1):49–61. https://doi.org/10.3390/neurolint14010004.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tops M, Koole SL, IJzerman H, Buisman-Pijlman FTA. Why social attachment and oxytocin protect against addiction and stress: Insights from the dynamics between ventral and dorsal corticostriatal systems. Pharmacol Biochem Behav. 2014;119:39–48. https://doi.org/10.1016/j.pbb.2013.07.015.

    Article  CAS  PubMed  Google Scholar 

  8. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–95. https://doi.org/10.1001/jama.284.13.1689.

    Article  CAS  PubMed  Google Scholar 

  9. Wang S-C, Chen Y-C, Lee C-H, Cheng C-M. Opioid addiction, genetic susceptibility, and medical treatments: a review. Int J Mol Sci. 2019;20(17):E4294. https://doi.org/10.3390/ijms20174294.

    Article  CAS  Google Scholar 

  10. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Lond Engl. 2017;390(10100):1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.

  11. Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief. 2018;329:1–8.

    Google Scholar 

  12. Daley DC, Smith E, Balogh D, Toscaloni J. Forgotten but not gone: the impact of the opioid epidemic and other substance use disorders on families and children. Commonwealth. 2018;20. https://doi.org/10.15367/com.v20i2-3.189.

  13. Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst. 2018;67(9):1–14.

    Google Scholar 

  14. Lueptow LM, Shashkova EC, Miller MG, Evans CJ, Cahill CM. Insights into the neurobiology of craving in opioid use disorder. Curr Anesthesiol Rep. 2020;10(4):378–87. https://doi.org/10.1007/s40140-020-00420-7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247–91. https://doi.org/10.1016/0165-0173(93)90013-p.

    Article  CAS  PubMed  Google Scholar 

  16. Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670–9. https://doi.org/10.1037/amp0000059.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry. 2020;87(1):44–53. https://doi.org/10.1016/j.biopsych.2019.05.023.

    Article  CAS  PubMed  Google Scholar 

  18. Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–80. https://doi.org/10.1007/s40263-019-00637-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. https://doi.org/10.1136/bmj.n784.

    Article  PubMed  Google Scholar 

  20. Durrani M, Bansal K. Methadone. In StatPearls, Treasure Island (FL): StatPearls Publishing. 2022. Accessed: 21 Sep 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK562216/.

  21. Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2019;76(15):1097–103. https://doi.org/10.1093/ajhp/zxz105.

    Article  Google Scholar 

  22. Murnane KS, Augustine JM, Quesnel M, Marshall L, Strom JG. A classroom activity to increase student pharmacists confidence in dealing with the opioid epidemic. Am J Pharm Educ. 2019;83(9):7199. https://doi.org/10.5688/ajpe7199.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jeanelle. Rising fentanyl use challenges current methadone induction protocols. Clin Advis. 2022. https://www.clinicaladvisor.com/home/the-waiting-room/fentanyl-challenges-current-methadone-induction-protocols/ (Accessed 03 Oct 2022).

  24. Randhawa PA, Brar R, Nolan S. Buprenorphine–naloxone ‘microdosing’: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. CMAJ Can Med Assoc J. 2020;192(3):E73. https://doi.org/10.1503/cmaj.74018.

    Article  CAS  Google Scholar 

  25. Edinoff AN, et al. Oxytocin, a novel treatment for methamphetamine use disorder. Neurol Int. 2022;14(1):1. https://doi.org/10.3390/neurolint14010015.

    Article  Google Scholar 

  26. The oxytocin receptor: from intracellular signaling to behavior | physiological reviews. https://journals.physiology.org/doi/full/10.1152/physrev.00031.2017?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org. (Accessed 21 Sep 2022).

  27. Sundar M, Patel D, Young Z, Leong K-C. Oxytocin and addiction: potential glutamatergic mechanisms. Int J Mol Sci. 2021;22(5):2405. https://doi.org/10.3390/ijms22052405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Russell J, Leng G, Bicknell R. Opioid tolerance and dependence in the magnocellular oxytocin system: a physiological mechanism? Exp Physiol. 1995;80(3):307–40. https://doi.org/10.1113/expphysiol.1995.sp003850.

    Article  CAS  PubMed  Google Scholar 

  29. Fan X-Y, Shi G, He X-J, Li X-Y, Wan Y-X, Jian L-Y. Oxytocin prevents cue-induced reinstatement of oxycodone seeking: involvement of DNA methylation in the hippocampus. Addict Biol. 2021;26(6):e13025. https://doi.org/10.1111/adb.13025.

    Article  CAS  PubMed  Google Scholar 

  30. Fan X-Y, Shi G, Zhao P. Methylation in Syn and Psd95 genes underlie the inhibitory effect of oxytocin on oxycodone-induced conditioned place preference. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2019;29(12):1464–75. https://doi.org/10.1016/j.euroneuro.2019.10.010.

    Article  CAS  Google Scholar 

  31. Gannon BM, Rice KC, Murnane KS. MDPV ‘high-responder’ rats also self-administer more oxycodone than their ‘low-responder’ counterparts under a fixed ratio schedule of reinforcement. Psychopharmacology. 2021;238(4):1183–92. https://doi.org/10.1007/s00213-021-05764-4.

    Article  CAS  PubMed  Google Scholar 

  32. Zanos P, et al. The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. Neuropsychopharmacology. 2014;39(4):4. https://doi.org/10.1038/npp.2013.285.

    Article  CAS  Google Scholar 

  33. Daigle KM, et al. Maternal responsivity and oxytocin in opioid-dependent mothers. Dev Psychobiol. 2020;62(1):21–35. https://doi.org/10.1002/dev.21897.

    Article  CAS  PubMed  Google Scholar 

  34. Weinberg MK, Tronick EZ. Beyond the face: an empirical study of infant affective configurations of facial, vocal, gestural, and regulatory behaviors. Child Dev. 1994;65(5):1503–15. https://doi.org/10.1111/j.1467-8624.1994.tb00832.x.

    Article  CAS  PubMed  Google Scholar 

  35. Moeini M, Omidi A, Sehat M, Banafshe HR. The effects of oxytocin on withdrawal, craving and stress response in heroin-dependent patients: a randomized, double-blind clinical trial. Eur Addict Res. 2019;25(1):41–7. https://doi.org/10.1159/000496194.

    Article  PubMed  Google Scholar 

  36. Woolley JD, et al. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology. 2016;233(13):2571–80. https://doi.org/10.1007/s00213-016-4308-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National Institutes of Health grant RO1 NS120676 to K.S.M.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA

    Amber N. Edinoff

  2. Louisiana Addiction Research Center, Shreveport, LA, 71103, USA

    Amber N. Edinoff, Elyse M. Cornett, Kevin S. Murnane & Alan D. Kaye

  3. Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA

    Saveen Sall & Kevin S. Murnane

  4. School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA

    Lauryn G. Honore, Ross M. Dies & Alexa R. Zaheri

  5. Department of Neurology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA

    Saurabh Kataria

  6. College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, 85004, USA

    Eric D. Jackson

  7. Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA

    Sahar Shekoohi, Elyse M. Cornett & Alan D. Kaye

  8. Department of Pharmacology, Louisiana State University Health Sciences Center at Shreveport, Toxicology & Neuroscience, Shreveport, LA, 71103, USA

    Elyse M. Cornett & Kevin S. Murnane

  9. Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, 95211, USA

    Adam M. Kaye

Authors
  1. Amber N. Edinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saveen Sall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lauryn G. Honore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ross M. Dies
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexa R. Zaheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saurabh Kataria
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eric D. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sahar Shekoohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elyse M. Cornett
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kevin S. Murnane
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Adam M. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alan D. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors listed have made a direct and intellectual contribution to the work and approved for publication.

Corresponding author

Correspondence to Sahar Shekoohi.

Ethics declarations

Conflict of Interest

None.

Human and Animal Rights and Informed Consent statement

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Acute Pain Medicine

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Edinoff, A.N., Sall, S., Honore, L.G. et al. The Use of Oxytocin for the Treatment of Opioid Use Disorder. Curr Pain Headache Rep 27, 89–97 (2023). https://doi.org/10.1007/s11916-023-01105-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-023-01105-6

Keywords

Search

Navigation